SLC22A3 polymorphisms do not modify pancreatic cancer risk, but may influence overall patient survival

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F75010330%3A_____%2F17%3A00011692" target="_blank" >RIV/75010330:_____/17:00011692 - isvavai.cz</a>

Alternative codes found

RIV/68378041:_____/17:00476783 RIV/65269705:_____/17:00066936 RIV/00216224:14110/17:00096878 RIV/00216208:11110/17:10332422 and 3 more

Result on the web

<a href="http://www.nature.com/articles/srep43812" target="_blank" >http://www.nature.com/articles/srep43812</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1038/srep43812" target="_blank" >10.1038/srep43812</a>

Result language

angličtina

Original language name

SLC22A3 polymorphisms do not modify pancreatic cancer risk, but may influence overall patient survival

Original language description

Expression of the solute carrier (SLC) transporter SLC22A3 gene is associated with overall survival of pancreatic cancer patients. This study tested whether genetic variability in SLC22A3 associates with pancreatic cancer risk and prognosis. Twenty four single nucleotide polymorphisms (SNPs) tagging the SLC22A3 gene sequence and regulatory elements were selected for analysis. Of these, 22 were successfully evaluated in the discovery phase while six significant or suggestive variants entered the validation phase, comprising a total study number of 1,518 cases and 3,908 controls. In the discovery phase, rs2504938, rs9364554, and rs2457571 SNPs were significantly associated with pancreatic cancer risk. Moreover, rs7758229 associated with the presence of distant metastases, while rs512077 and rs2504956 correlated with overall survival of patients. Although replicated, the association for rs9364554 did not pass multiple testing corrections in the validation phase. Contrary to the discovery stage, rs2504938 associated with survival in the validation cohort, which was more pronounced in stage IV patients. In conclusion, common variation in the SLC22A3 gene is unlikely to significantly contribute to pancreatic cancer risk. The rs2504938 SNP in SLC22A3 significantly associates with an unfavorable prognosis of pancreatic cancer patients. Further investigation of this SNP effect on the molecular and clinical phenotype is warranted.

Czech name

—

Czech description

—

Type

J_imp - Article in a specialist periodical, which is included in the Web of Science database

CEP classification

—

OECD FORD branch

30101 - Human genetics

Project

Result was created during the realization of more than one project. More information in the Projects tab.

Continuities

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)<br>I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Publication year

2017

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

Scientific Reports

ISSN

2045-2322

e-ISSN

—

Volume of the periodical

7

Issue of the periodical within the volume

March

Country of publishing house

GB - UNITED KINGDOM

Number of pages

11

Pages from-to

nestrankovano

UT code for WoS article

000395686300001

EID of the result in the Scopus database

—